We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$60.9M
Cap. Flow
+$27.1M
Cap. Flow %
5.19%
Top 10 Hldgs %
45.15%
Holding
120
New
43
Increased
21
Reduced
16
Closed
38

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$22.2M
2
BHVN icon
Biohaven
BHVN
+$17.4M
3
MBX
MBX Biosciences
MBX
+$14.3M
4
CGON icon
CG Oncology
CGON
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.9M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$28.9M
2
ACLX
Arcellx
ACLX
+$21.7M
3
TWST icon
Twist Bioscience
TWST
+$21.3M
4
TERN
Terns Pharmaceuticals
TERN
+$17.6M
5
ROIV icon
Roivant Sciences
ROIV
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
51
Jade Biosciences
JBIO
$1.27B
$2.16M 0.41%
+154,034
New +$2.23M
TWST icon
52
Twist Bioscience
TWST
$5.84B
$2.05M 0.39%
43,110
-475,245
-92% -$21.3M
MPLT
53
MapLight Therapeutics
MPLT
$1.72B
$2.03M 0.39%
100,000
– –
AVTX icon
54
Avalo Therapeutics
AVTX
$1.02B
$2.01M 0.39%
134,742
-810
-0.6% -$12.7K
IONS icon
55
Ionis Pharmaceuticals
IONS
$8.99B
$1.98M 0.38%
+26,385
New +$2.08M
IMCR icon
56
Immunocore
IMCR
$1.78B
$1.92M 0.37%
+63,543
New +$2.06M
FBRX icon
57
Forte Biosciences
FBRX
$1B
$1.5M 0.29%
+58,020
New +$1.67M
SION
58
Sionna Therapeutics
SION
$2.23B
$1.46M 0.28%
+36,540
New +$1.39M
SABS icon
59
SAB Biotherapeutics
SABS
$271M
$1.44M 0.28%
375,000
+228,442
+156% +$911K
SLDB icon
60
Solid Biosciences
SLDB
$858M
$1.41M 0.27%
+195,403
New +$1.26M
LPCN icon
61
Lipocine
LPCN
$18.4M
$1.28M 0.25%
+160,420
New +$1.4M
QURE icon
62
uniQure
QURE
$2.77B
$1.28M 0.24%
78,066
+34,581
+80% +$700K
LBRX
63
LB Pharmaceuticals
LBRX
$901M
$1.23M 0.24%
+50,000
New +$1.15M
CCCC icon
64
C4 Therapeutics
CCCC
$408M
$1.19M 0.23%
+453,236
New +$1.07M
EW icon
65
Edwards Lifesciences
EW
$49.4B
$1.17M 0.22%
+14,588
New +$1.2M
CAPR icon
66
Capricor Therapeutics
CAPR
$1.13B
$1.14M 0.22%
37,592
+19,739
+111% +$526K
BDSX icon
67
Biodesix
BDSX
$209M
$1.02M 0.19%
+70,004
New +$868K
SRRK icon
68
CALL
Scholar Rock
SRRK
$6.33B
$588K 0.11%
100,000
-177,000
-64% -$7.93M
STRO icon
69
Sutro Biopharma
STRO
$391M
$580K 0.11%
+23,295
New +$421K
RVMD icon
70
PUT
Revolution Medicines
RVMD
$39.6B
$525K 0.1%
+100,000
New +$10.1M
SPRB
71
Spruce Biosciences
SPRB
$120M
$416K 0.08%
+6,360
New +$439K
TYRA icon
72
CALL
Tyra Biosciences
TYRA
$1.91B
$290K 0.06%
+100,000
New +$3.24M
IMVT icon
73
CALL
Immunovant
IMVT
$8.27B
$255K 0.05%
+100,000
New +$2.59M
XBI icon
74
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$164K 0.03%
+150,000
New +$18.7M
SNDX icon
75
CALL
Syndax Pharmaceuticals
SNDX
$2.02B
$90K 0.02%
+150,000
New +$3.26M
1 2
3
4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Stempoint Capital held 120 positions worth $522M, down 10% from $583M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Stempoint Capital deployed $27.1M of net new capital in Q1 2026, opening 43 new positions and adding to 21 existing holdings. Its largest new stake was Biohaven: 1,594,491 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $21.3M trimmed.

  • Stempoint Capital's largest Q1 2026 buy was Biohaven: 1,594,491 shares worth $13.5M.
  • Stempoint Capital added most to Revolution Medicines in Q1 2026, an estimated $22.2M increase.
  • Stempoint Capital's biggest Q1 2026 reduction was Twist Bioscience, cutting an estimated $21.3M.
  • Stempoint Capital fully exited Centessa Pharmaceuticals in Q1 2026, selling an estimated $28.9M.
  • Stempoint Capital's ten largest holdings make up 45% of its $522M portfolio in Q1 2026.
  • Stempoint Capital opened 43 new positions and closed 38 in Q1 2026.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $522M.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.